News Release

Advances in therapeutic agents targeting quiescent cancer cells

Peer-Reviewed Publication

Compuscript Ltd

Announcing a new review article publication for Acta Materia Medica journal. Quiescent cancer cells (QCCs) reversibly reside in G0 phase, thus allowing them to survive chemotherapy and radiotherapy, which generally target proliferating cells. Surviving QCCs may re-proliferate, and consequently result in cancer progression, recurrence, and metastasis. Therefore, understanding the key players governing QCC survival and activation is crucial for developing QCC-targeting agents.

The authors of this article present an overview of the mechanisms underlying the regulation of QCC status and  recent advances in the development of QCC-targeting therapeutic agents and their underlying mechanisms. The development of effective therapeutic modalities that target QCCs may enable new cancer treatments to prevent cancer progression and recurrence.

Article Reference: Wan Najbah Nik Nabil, Zhichao Xi and Mengfan Liu et al. Advances in therapeutic agents targeting quiescent cancer cells. Acta Materia Medica. Vol. 1(1). DOI: 10.15212/AMM-2021-0005.b

Keywords: quiescence, dormancy, neoplasm, mechanism, therapeutic agent

# # # # # #

Acta Materia Medica welcomes the submission of research articles, review articles, databases, mini reviews, commentaries, editorials, short communications, case report articles and study protocols.

Submission Process

Submissions to Acta Materia Medica are made using ScholarOne, the online submission and peer review system. Registration and access are available at

Queries about the journal can be sent to

Please visit to learn more about the journal.

Editorial Board:

There are no author submission or article processing fees.


Follow Acta Materia Medica on Twitter  ; Facebook (

eISSN 2737-7946

# # # # # #

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.